Last reviewed · How we verify
Yellow Fever 17DD Vaccine
The Yellow Fever 17DD vaccine stimulates the immune system to produce antibodies and cellular immunity against yellow fever virus by using a live attenuated (weakened) viral strain.
The Yellow Fever 17DD vaccine stimulates the immune system to produce antibodies and cellular immunity against yellow fever virus by using a live attenuated (weakened) viral strain. Used for Prevention of yellow fever in endemic regions and travelers to yellow fever-endemic areas.
At a glance
| Generic name | Yellow Fever 17DD Vaccine |
|---|---|
| Sponsor | Centers for Disease Control and Prevention |
| Drug class | live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The 17DD strain is a live attenuated yellow fever virus that replicates in vaccinated individuals without causing disease, triggering both humoral (antibody) and cell-mediated immune responses. This generates protective immunity against wild-type yellow fever virus infection. The vaccine has been used for decades and provides durable protection in the majority of vaccinees.
Approved indications
- Prevention of yellow fever in endemic regions and travelers to yellow fever-endemic areas
Common side effects
- Headache
- Myalgia
- Fever
- Injection site reaction
- Fatigue
Key clinical trials
- Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old (PHASE4)
- Clinical Study of Immunity Duration of Yellow Fever Vaccine in Military
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Yellow Fever 17DD Vaccine CI brief — competitive landscape report
- Yellow Fever 17DD Vaccine updates RSS · CI watch RSS
- Centers for Disease Control and Prevention portfolio CI